Tag: CETP inhibitor

MSD’s CETP inhibitor cuts heart risk by 9 percent

by Selina McKee | Aug 30, 2017 | News | 0

MSD has revealed that its CETP inhibitor anacetrapib reduced the risk of major coronary events by 9 percent versus placebo in patients with cardiovascular disease already taking LDL-C lowering therapy alongside atorvastatin.

MSD’s CETP inhibitor lowers risk of cardiac events

by Selina McKee | Jun 28, 2017 | News | 0

MSD’s CETP inhibitor anacetrapib has hit its key target in the late-stage REVEAL study, showing a significant reduction in major coronary events in at-risk patients already on a cholesterol-lowering regimen.